In Europe, PLENVU® is indicated in adults for bowel cleansing prior to any procedure requiring a clean bowel.[ii]

PLENVU is a trademark of the Norgine group of companies.

About XIFAXAN® 550mg

XIFAXAN® (rifaximin) 550mg is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age.[iii]

Norgine currently holds marketing rights for rifaximin–α (XIFAXAN® 550mg, also known as TARGAXAN® 550mg in the UK and Belgium) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden and United Kingdom.

XIFAXAN and TARGAXAN are under license from Alfasigma S.p.A.
XIFAXAN and TARGAXAN are registered trademarks of the Alfasigma group of companies, licensed to the Norgine group of companies.

About Norgine

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net product sales were EUR 345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

We use strictly necessary, performance and functionality cookies to give you the best experience while using this website. We do not employ any marketing cookies on this website. Only continue if you accept. AcceptRead more